Please assess the completion status of the following clinical trial:

Trial Title: Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~- Male or female patient \<60 years old with relapsing multiple sclerosis (RMS) either treated for at least 6 months with 7 or 14 mg teriflunomide in one of the studies LTS6048 or LTS6050, or treated with a stable dose of interferon-β-1 for at least 6 months.~Exclusion Criteria:~* Concomitant infectious pathology at the time of vaccination;~* MS relapse within 1 month before vaccination;~* Systemic corticosteroids within 1 month before the vaccination;~* Any contraindication to influenza vaccine;~* Any vaccination within the last 6 months;~* Prior use of any investigational drug or participation to a clinical trial within 1 year (only for patients under interferon-β-1);~* Prior or concomitant use (for a minimum of 1 year before study entry) of cladribine, mitoxantrone, or other immunosuppressant agents such as azathioprine, cyclophosphamide, cyclosporin, methotrexate, mycophenolate, natalizumab (Tysabri®), leflunomide or fingolimod or other immunomodulator/immunosuppressant in development;~* Prior or concomitant use of glatiramer acetate within 1 year before study entry;~* Prior or concomitant use of intravenous immunoglobulins within 3 months before study entry;~* Pregnant or breast feeding women;~* Woman of childbearing potential without adequate contraception.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 59 Years
- Healthy Volunteers: f

Study Arms:
- Teriflunomide 7 mg (Type: EXPERIMENTAL): Influenza vaccine in participants treated with teriflunomide 7 mg for at least 6 months
- Teriflunomide 14 mg (Type: EXPERIMENTAL): Influenza vaccine in participants treated with teriflunomide 14 mg for at least 6 months
- IFN-β-1 (Type: ACTIVE_COMPARATOR): Influenza vaccine in participants treated with a stable dose of Interferon-β-1 (IFN-β-1) for at least 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).